Lord Rennard

HL9905 • Medical Treatments: Innovation

To ask His Majesty's Government what assessment they have made of the effectiveness of the National Institute for Health and Care Excellence's (NICE) evaluation processes at reflecting the pace of innovation in medical technologies, in particular for chronic conditions such as type 1 and 2 diabetes; and what assessment they have made of increasing NICE's cost-effectiveness threshold in line with the voluntary scheme growth rates since 2014.

HL9906 • NHS: Drugs

To ask His Majesty's Government what assessment they have made of adopting reimbursed access at the point of marking authorisation for medicines; and what assessment they have made of the impact of cost-effectiveness appraisals after real world use on the consideration of potential long-term clinical and patient benefits.

HL9907 • Medical Treatments: Innovation

To ask His Majesty's Government whether long-term clinical benefits and broader impacts, such as economic activity and emotional wellbeing, of medical innovations are routinely considered by the National Institute for Health and Care Excellence; and what assessment they have made of incorporating consideration of those impacts into evolving cost-effectiveness technologies.

HL9908 • Diabetes: Medical Treatments

To ask His Majesty's Government how they are working with NHS England to ensure equitable access to diabetes innovations, particularly for patients from disadvantaged and ethnic minority backgrounds.

HL9909 • Medical Treatments

To ask His Majesty's Government what assessment they have made of the progress of the National Institute for Health and Care Excellence towards their priorities for 2025–26, including diabetes, and the impact of those priorities on patient access to novel technologies and treatments.

HL9910 • Diabetes: Gender

To ask His Majesty's Government, in regard to the NHS 10 Year Health Plan for England, what assessment they have made of opportunities to identify genetic risk for diabetes, and what plans they have to implement that genetic testing as part of the shift to diabetes prevention.

HL9845 • Tobacco: Smuggling

To ask His Majesty's Government how many (1) calls, and (2) online submissions, have been made to HMRC fraud hotline services in relation to illicit tobacco in each of the past ten years.

HL9700 • Smoking: Health Services

To ask His Majesty's Government what assessment they have made of the potential cost savings to the NHS and social care system of implementing automatic stop smoking support at NHS touchpoints; and how will that inform future funding decisions.

HL9701 • Cancer: Health Services

To ask His Majesty's Government whether the national cancer plan will include steps to integrate exercise, nutrition and well-being support into prehabilitation and rehabilitation programmes for all cancer patients, as recommended in The White Rose Cancer Report, published by Yorkshire Cancer Research on 18 June; and what plans they have to adopt the ROSE model to ensure equity in research funding and implementation across the country.

HL9702 • Cancer: Accident and Emergency Departments

To ask His Majesty's Government what steps they are taking to reduce the number of people diagnosed with cancer in an emergency care setting in (1) Yorkshire, and (2) other regions of the country.

HL9188 • Public Duty Costs Allowance

To ask His Majesty's Government how much has been paid through the Public Duty Costs Allowance since its inception to (1) each former Prime Minister and Deputy Prime Minister, and (2) in total.

HL9189 • Public Duty Costs Allowance

To ask His Majesty's Government what they consider the public duties of former Prime Ministers to be in relation to the Public Duty Cost Allowance; and what plans they have to review the Public Duty Cost Allowance to increase transparency.

HL9190 • Public Duty Costs Allowance

To ask His Majesty's Government what steps they are taking to ensure that claims by former Prime Ministers and Deputy Prime Minister through the Public Duty Costs Allowance are not used to fund income-generating projects.

HL9191 • Public Duty Costs Allowance

To ask His Majesty's Government what assessment they have made of the need to scrutinise claims for Public Duty Costs Allowance.

HL8489 • Electronic Cigarettes and Tobacco: Prices

To ask His Majesty's Government whether they will publish the current price elasticities used to make forecasts of the tobacco and vaping markets.

HL8189 • Food: Advertising

To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 22 May (HLWS662), what assessment they have made of the effectiveness of the Advertising Standards Authority in its role as the frontline regulator of the measures in the Health and Care Act 2022 about the advertising of unhealthy food and drink on TV and online.

HL8063 • Food: Advertising

To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 22 May (HLWS662), whether they consulted or informed any public health organisations of the decision to delay the legislation to regulate unhealthy food and drink advertisements on TV and online before publishing that statement.

HL8064 • Food: Advertising

To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 22 May (HLWS662), on what date the food and media companies that signed the letter published on the Advertising Association's website were informed of the decision to delay regulations on TV and online advertising of unhealthy food.

HL8065 • Food: Advertising

To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 22 May (HLWS662), whether they considered alternatives to delaying the regulation of the advertising of unhealthy food on TV and online.

HL8066 • Food: Advertising

To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 22 May (HLWS662), what representations they received from (1) the food and drink industry, and (2) the advertising industry, about the regulations to restrict the advertising of unhealthy food; and whether those representations were a factor in the decision to delay those regulations.